NVCR NovoCure Ltd
Price (delayed)
$18.55
Market cap
$2.04B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.56
Enterprise value
$2.55B
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating
Highlights
The gross profit has increased by 23% YoY and by 6% QoQ
The company's revenue rose by 19% YoY and by 4.8% QoQ
NVCR's EPS is up by 20% year-on-year but it is down by 12% since the previous quarter
The net income has grown by 19% YoY but it has contracted by 13% from the previous quarter
The company's quick ratio has shrunk by 74% YoY
NovoCure's debt has increased by 13% YoY
Key stats
What are the main financial stats of NVCR
Market
Valuations
Earnings
Shares outstanding
109.92M
Market cap
$2.04B
Enterprise value
$2.55B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.57
Price to sales (P/S)
3.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.21
Revenue
$605.22M
Gross profit
$468.04M
Operating income
-$170.5M
Net income
-$168.63M
EBIT
-$170.5M
EBITDA
-$159.26M
Free cash flow
-$69.22M
Per share
Balance sheet
Liquidity
EPS
-$1.56
EPS diluted
-$1.56
Free cash flow per share
-$0.64
Book value per share
$3.33
Revenue per share
$5.61
TBVPS
$11.51
Total assets
$1.24B
Total liabilities
$880.61M
Debt
$675.43M
Equity
$360.18M
Working capital
$350.2M
Debt to equity
1.88
Current ratio
1.46
Quick ratio
1.42
Net debt/EBITDA
-3.2
Margins
Efficiency
Dividend
EBITDA margin
-26.3%
Gross margin
77.3%
Net margin
-27.9%
Operating margin
-28.2%
Return on assets
-14.1%
Return on equity
-46.8%
Return on invested capital
-14.8%
Return on capital employed
-35.2%
Return on sales
-28.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVCR stock price
How has the NovoCure stock price performed over time
Intraday
4.39%
1 week
19.06%
1 month
-6.22%
1 year
50.32%
YTD
-37.75%
QTD
4.1%
Financial performance
How have NovoCure's revenue and profit performed over time
Revenue
$605.22M
Gross profit
$468.04M
Operating income
-$170.5M
Net income
-$168.63M
Gross margin
77.3%
Net margin
-27.9%
NovoCure's operating margin has increased by 38% YoY but it has decreased by 2.5% QoQ
NovoCure's net margin has increased by 31% YoY but it has decreased by 8% from the previous quarter
NovoCure's operating income has increased by 27% YoY but it has decreased by 7% QoQ
The gross profit has increased by 23% YoY and by 6% QoQ
Growth
What is NovoCure's growth rate over time
Valuation
What is NovoCure stock price valuation
P/E
N/A
P/B
5.57
P/S
3.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.21
NVCR's EPS is up by 20% year-on-year but it is down by 12% since the previous quarter
The price to book (P/B) is 71% lower than the 5-year quarterly average of 19.3 and 6% lower than the last 4 quarters average of 5.9
NVCR's price to sales (P/S) is 77% lower than its 5-year quarterly average of 14.7 and 11% lower than its last 4 quarters average of 3.7
The company's revenue rose by 19% YoY and by 4.8% QoQ
Efficiency
How efficient is NovoCure business performance
NVCR's return on sales is up by 38% year-on-year but it is down by 2.5% since the previous quarter
The company's return on assets rose by 21% YoY but it fell by 11% QoQ
NovoCure's ROIC has decreased by 15% from the previous quarter but it has increased by 11% YoY
NovoCure's return on equity has decreased by 13% QoQ but it has increased by 9% YoY
Dividends
What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVCR.
Financial health
How did NovoCure financials performed over time
NovoCure's total assets is 41% more than its total liabilities
The company's current ratio has shrunk by 75% YoY and by 2% QoQ
The company's quick ratio has shrunk by 74% YoY
NovoCure's debt is 88% more than its equity
NVCR's debt to equity is up by 15% YoY
NovoCure's debt has increased by 13% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.